FGEN Insider Trading

Insider Ownership Percentage: 1.98%
Insider Buying (Last 12 Months): $164,133.91
Insider Selling (Last 12 Months): $0.00

FibroGen Insider Trading History Chart

This chart shows the insider buying and selling history at FibroGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$138kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

FibroGen Share Price & Price History

Current Price: $0.31
Price Change: Price Decrease of -0.0142 (-4.33%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for FGEN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.31Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for FibroGen (NASDAQ:FGEN)

72.71% of FibroGen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at FGEN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$622kbought$2.11MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M-$1M$0$1M$2MTotal InflowsTotal Outflows
FibroGen logo
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Read More on FibroGen

Today's Range

Now: $0.31
Low: $0.30
High: $0.34

50 Day Range

MA: $0.46
Low: $0.31
High: $0.77

52 Week Range

Now: $0.31
Low: $0.18
High: $2.40

Volume

2,286,803 shs

Average Volume

2,338,200 shs

Market Capitalization

$31.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Who are the company insiders with the largest holdings of FibroGen?

FibroGen's top insider investors include:
  1. Thane Wettig (CEO)
  2. Enrique A Conterno (CEO)
  3. James A Schoeneck (Director)
  4. Christine Chung (SVP)
  5. Mark Eisner (Insider)
  6. Mark Eisner (EVP)
  7. Thane Wettig (Insider)
  8. Deyaa Adib (Insider)
  9. Juan Graham (CFO)
  10. Jeffrey William Henderson (Director)
  11. Benjamin Cravatt (Director)
Learn More about top insider investors at FibroGen.

Who are the major institutional investors of FibroGen?

FibroGen's top institutional investors include:
  1. Primecap Management Co. CA — 4.58%
  2. Renaissance Technologies LLC — 1.35%
  3. Marshall Wace LLP — 1.26%
  4. Geode Capital Management LLC — 1.05%
  5. Two Sigma Advisers LP — 0.87%
  6. Millennium Management LLC — 0.82%
Learn More about top institutional investors of FibroGen stock.

Which institutional investors are selling FibroGen stock?

In the previous quarter, FGEN stock was sold by these institutional investors:
  1. Primecap Management Co. CA
  2. LMR Partners LLP
  3. Assenagon Asset Management S.A.
  4. Marshall Wace LLP
  5. Millennium Management LLC
  6. Sei Investments Co.
  7. Price T Rowe Associates Inc. MD
  8. Geode Capital Management LLC

Which institutional investors are buying FibroGen stock?

During the last quarter, FGEN stock was bought by institutional investors including:
  1. Renaissance Technologies LLC
  2. Mackenzie Financial Corp
  3. Squarepoint Ops LLC
  4. Two Sigma Advisers LP
  5. Franklin Street Advisors Inc. NC
  6. Two Sigma Investments LP
  7. Velan Capital Investment Management LP
  8. XTX Topco Ltd
During the last year, these company insiders have bought FibroGen stock:
  1. Thane Wettig (CEO)
  2. Enrique A Conterno (CEO)
  3. James A Schoeneck (Director)
Learn More investors buying FibroGen stock.